In this study, we report that TMPRSS4 upregulates bcl-2 and survivin to enhance cancer cell survival, and inhibits anoikis and drug treatment sensitivity, potentially via upregulation of AP-1, Sp1, and NF-κB. The gene discussed is JUN; the disease is cancer.